Meet Sprout

We’re committed to breakthrough firsts in women’s sexual health.

Sit At Our Glass Table

Novel ideas fuel our entrepreneurial passion. Sit with us at our glass table, where we have lunch together daily, to get a taste of our culture. At Sprout, we celebrate ownership, boldness, quirkiness, learning, family and appreciation. They are central to what we stand for and what we’re trying to collectively accomplish.

We’re On A Mission

Singular in our focus, our leadership team sold off a successful business in male sexual health to take on the pursuit of this much needed scientific and societal breakthrough for women. Led by a woman dedicated to this first for women, our CEO, Cindy Whitehead, and the work of the committed Sprout team has been featured on news outlets including ABC 20/20, Yahoo! News with Katie Couric, Good Morning America, Nightline, Huffington Post, and CBS This Morning.

We'd Love to Hear From You

Share your story (thank you to all the women and couples who already have!), your interest in joining us or your inquiries. We’d love to hear from you!

To Join Us, click here.

Learn Our Latest

Addyi Certification Press Release and Distribution Strategy

Sprout Pharmaceuticals, Inc. (Sprout) announced today that healthcare prescribers and pharmacies can now complete training to become certified to prescribe or dispense the medication through the Addyi Risk Evaluation and Mitigation Strategy (REMS) Program.

Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.

Sprout Pharmaceuticals Receives FDA Approval of ADDYI™ (Flibanserin 100 MG)

Sprout Pharmaceuticals, Inc. (Sprout) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of Addyi™ (flibanserin 100 mg) (pronounced add-ee), a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.